Streetwise Live! Presents Vox Royalty Corp. (VOX:TSX.V) on 03/12/2021. Learn More

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Aclaris Shares Triple in Value on Positive Topline Data from Phase 2a Rheumatoid Arthritis Trial

  ()
Shares of Aclaris Therapeutics Inc. soared to a new 52-week high after the company reported positive preliminary topline data from its Phase 2a trial of oral ATI-450 for moderate to severe rheumatoid arthritis. read more >
News Update

Life Sciences Firm Partners with University to Develop Biosynthetic Psilocybin

News Update
  ()
Revive Therapeutics entered into a research agreement with North Carolina State University to develop psilocybin utilizing a natural biosynthesis enzymatic platform. read more >
News Update

Neurosciences Firm Outlines Strategic Priorities for 2021

News Update
  ()
ProMIS Neurosciences discusses its four priority areas in 2021. read more >

As Psychedelics Move Mainstream, Small Cap Positions Itself at the Center of the Industry

  ()
Two year old DELIC Corp. has gotten in on the ground floor of the nascent psychedelic sector. read more >

Mesoblast Reports Phase 3 Trial Data Showing Substantial Reductions in Cardiac and Stroke Events in CHF Patients

  ()
Shares of Mesoblast Ltd. traded 36% higher after the company reported positive results from its Phase 3 DREAM-HF study showing that a single dose of rexlemestrocel-L provided very significant decreases in heart attacks, strokes and cardiac death in patients diagnosed with chronic heart failure. read more >

A Novel, First-in-Class Blood Clotting Agent Takes Shape as a Bloody Compelling Investment

Contributed Opinion
  ()
Private start-up RxMP's safe way to stop bleeding inexpensively is already the envy of bigger players, states Dr. KSS, MD, PhD, editor-in-chief of PubBio.co. Can it go the distance through proof of concept? read more >

Chimerix Expands Late-Stage Oncology Pipeline Through $78M Oncoceutics Acquisition

  ()
Chimerix Inc. shares traded 65% higher after the company reported it entered into an agreement to acquire Oncoceutics Inc. in a combination stock and cash deal valued at $78 million plus milestone incentives totaling up to $360 million. read more >
News Update

Pharma Developer Outlines 2021 Clinical Program Initiatives

News Update
  ()
Algernon Pharmaceuticals provided an update detailing its plans for 2021 clinical trials. read more >

Biopharma's Acute Migraine Trial Yields Positive Efficacy, Safety Results

Research Report
  ()
The recently announced topline results from Axsome Therapeutics' MOVEMENT study are reviewed in a Ladenburg Thalmann report. read more >
News Update

Biopharma Recaps 2020 Accomplishments in COVID-19, Idiopathic Pulmonary Disease

News Update
  ()
Algernon Pharmaceuticals reports that it is aggressively advancing its repurposed drug, Ifenprodil. read more >
News Update

Biopharma Appoints Adviser for Phase 3 COVID-19 Trial

News Update
  ()
Revive Therapeutics selects Dr. John Fahy, California-based pulmonary medicine expert and researcher, to join its team. read more >

Pandion Shares Get a Lift from Positive Top-Line Data in Phase 1a Autoimmune Disease Trial

  ()
Pandion Therapeutics shares traded 35% higher after the company reported positive top-line data from its Phase 1a clinical study of PT101 for treating autoimmune diseases including ulcerative colitis and systemic lupus erythematosus. read more >

Biotech On Track for Trio of Drugs in Clinical Trials in 2021

Research Report
  ()
The next steps for advancing Oramed Pharmaceuticals' oral therapy candidates are provided in an H.C. Wainwright & Co. report. read more >

California Biotech Advances Two COVID-19 Products

Research Report
  ()
Recent news concerning Sorrento Therapeutics' SARS-CoV-2 virus test and antibodies is discussed in a Dawson James Securities report. read more >
News Update

Phase 3 COVID-19 Trial on Track for Independent Safety, Efficacy Review

News Update
  ()
Revive Therapeutics plans to apply for emergency use authorization of its drug Bucillamine as a treatment for the indication. read more >

Myovant Shares Rise 25% on $4.2 Billion Development Partnership with Pfizer

  ()
Shares of Myovant Sciences established a new 52-week high after the company entered into an agreement with Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) for advanced prostate cancer and relugolix combination tablet for women's health in the U.S. and Canada. read more >

Positive Data from Phase 3 Adult ADHD Trial Lifts Supernus Pharma Shares 17% Higher

  ()
Supernus Pharmaceuticals shares reached a new 52-week high price after the company reported positive results from its Phase 3 Study of SPN-812 for treating adults with attention deficit hyperactivity disorder. read more >
News Update

Life Sciences Company to Acquire Psychedelic Pharmaceutical Firm's Psilocybin Program

News Update
  ()
Revive Therapeutics reported it has submitted a non-binding letter of intent to acquire 100% of PharmaTher Inc.'s psilocybin program. read more >

Agios Pharma Agrees to Sell Oncology Business to Servier for US$2 Billion Plus Royalties

  ()
Shares of Agios Pharmaceuticals traded 30% higher after the company reported that it has agreed to sell its oncology research business to France's Servier Group in a transaction valued up to US$2 billion in cash plus future royalties. read more >
News Update

Pharma Developer Provides Interim Update from Phase 2b Ifenprodil COVID-19 Study

News Update
  ()
Algernon Pharmaceuticals provided additional interim data from its Phase 2b/3 Ifenprodil COVID-19 study outlining several potential primary endpoints for the Phase 3 portion of the trial. read more >

Humanigen Shares Rise on Completing Phase 1 Brain Cancer Trial Enrollment

  ()
Shares of Humanigen Inc. traded 24% higher after the company reported that it had successfully completed enrollment of patients in a Phase 1 Study of ifabotuzumab in glioblastoma multiforme. read more >

Why XPhyto's PCR Test Kit Is a Game Changer for COVID-19 Testing

Contributed Opinion
  ()
Extraordinary achievement promises to help turn the tide against the COVID 19 pandemic, Knox Henderson writes. read more >
News Update

Pharma Developer Reports Interim Data Is Trending Positively in Phase 2b/3 COVID-19 Trial

News Update
  ()
Algernon Pharmaceuticals reported that interim data from its Phase 2b/3 Ifenprodil COVID-19 study is showing very positive signs of reducing the need for mechanical ventilators. read more >

US Specialty Pharma Makes 'Another Acquisition to Bolster Topline'

Research Report
  ()
The transaction details and expected impact on Aytu BioScience's balance sheet are provided in a Ladenburg Thalmann report. read more >

Analyst: Small Cap's Interim COVID-19 Trial Data Show 'Two Positive Early Trends'

Research Report
  ()
Partial Phase 2b results of this evaluation of Algernon Pharmaceuticals' antagonist are provided in a Mackie Research Capital Corp. report. read more >
Showing Results: 26 to 50 of 118 Prev Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe